Prevention of COPD exacerbations: A European Respiratory Society/ American Thoracic Society guideline

European Respiratory Journal

Volumn 50, Issue 3, 2017, Pages

  Wedzicha, Jadwiga A ^a   Calverley, Peter M A ^b   Albert, Richard K ^c   Anzueto, Antonio ^d   Criner, Gerard J ^e   Hurst, John R ^f   Miravitlles, Marc ^g   Papi, Alberto ^h   Rabe, Klaus F ⁱ   Rigau, David ^j   Sliwinski, Pawel ^k   Tonia, Thomy ^l   Vestbo, Jørgen ^m   Wilson, Kevin C ⁿ   Krishnan, Jerry A ^o  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h UNIVERSITY OF FERRARA   (Italy)

ⁱ UNIVERSITY OF KIEL   (Germany)

^j Iberoamerican Cochrane Center   (Spain)

^k NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

^l UNIVERSITY OF BERN   (Switzerland)

^m UNIVERSITY OF MANCHESTER   (United Kingdom)

ⁿ BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMBROXOL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CARBOCISTEINE; LONG ACTING DRUG; MACROLIDE; MUCOLYTIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE IV INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROFLUMILAST; AMINOPYRIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE; QUINOLONE DERIVATIVE;

AMERICAN; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST; DIARRHEA; DISEASE EXACERBATION; EUROPEAN; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; FEASIBILITY STUDY; HEARING IMPAIRMENT; HUMAN; INFORMATION RETRIEVAL; INSOMNIA; MEDICAL SOCIETY; MENTAL DISEASE; NAUSEA; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROGRAM ACCEPTABILITY; PUBLICATION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SLEEP DISORDER; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; PATHOPHYSIOLOGY; SECONDARY PREVENTION; STANDARDS; UNITED STATES;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AMINOPYRIDINES; BENZAMIDES; CYCLOPROPANES; DISEASE PROGRESSION; FLUOROQUINOLONES; HUMANS; MACROLIDES; MUSCARINIC ANTAGONISTS; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SECONDARY PREVENTION; SOCIETIES, MEDICAL; UNITED STATES;

EID: 85029471738     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.02265-2016     Document Type: Review

References (36)

1. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
2. Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-1422.
3. Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: A 2 year follow up study. Thorax 2004; 59: 387-395.
4. Soler-Cataluña JJ, Martinez-Gracía MA, Roman Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-931.
5. Guyatt GH, Oxman AD, Vist G, et al. Rating quality of evidence and strength of recommendations GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-926.
6. Wedzicha JA, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: A European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2017; 49: 1600791.
7. National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease: Management of chronic pulmonary obstructive disease in adults in primary and secondary care ( partial update). London, National Clinical Guideline Centre, 2010.
8. Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; 7: CD001287.
9. Decramer M, Rutten-van Mölken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): A randomised placebo-controlled trial. Lancet 2005; 365: 1552-1560.
10. Malerba M, Ponticiello A, Radaeli A, et al. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial). Pulm Pharmacol Ther 2004; 17: 27-34.
11. Schermer T, Chavannes N, Dekhuijzen R, et al. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir Med 2009; 103: 542-551.
12. Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): A randomised placebo-controlled study. Lancet 2008; 371: 2013-2018.
13. Tse HN, Raiteri L, Wong KY, et al. High-dose N-acetylcysteine in stable COPD: The 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest 2013; 144: 106-118.
14. Zheng JP, Wen FQ, Bai CX, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): A randomised, double-blind placebo-controlled trial. Lancet Respir Med 2014; 2: 187-194.
15. Cegla U. Langzeittherapie uber 2 Jahre mit Ambroxol (Mucosolvan) Retardkapseln bei Patienten mit chronischer Bronchitis. Ergebnisse einer Doppelblindstudie an 180 Patienten. [Long-term therapy over 2 years with ambroxol (Mucosolvan) retard capsules in patients with chronic bronchitis. Results of a double-blind study of 180 patients.] Prax Klin Pneumonol 1988; 42: 715-721.
16. Cazzola M, Calzetta L, Page C, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: A meta-analysis. Eur Respir Rev 2015; 24: 451-461.
17. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Eur Respir J 2017; 49: 1700214.
18. Criner GJ, Bourbeau J, Diekemper RL, et al. Executive summary: Prevention of acute exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest 2015; 147: 883-893.
19. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364: 1093-1103.
20. Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): A randomised, blinded, parallel-group study. Lancet Respir Med 2013; 1: 524-533.
21. Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 154-161.
22. Rennard SI, Calverley PM, Goehring UM, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast -the importance of defining different subsets of patients with COPD. Respir Res 2011; 12: 18.
23. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomised clinical trials. Lancet 2009; 374: 685-694.
24. Martinez FJ, Calverley PMA, Goehring UM, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): A multicentre randomised controlled trial. Lancet 2015; 385: 857-866.
25. Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013; 5: CD002309.
26. Sethi S, Jones PW, Schmitt Terron M, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: A randomized controlled trial. Respir Res 2010; 11: 10.
27. Lee HW, Lee JK, Kim E, et al. The effectiveness and safety of fluoroquinolone-containing regimen as a first-line treatment for drug-sensitive pulmonary tuberculosis: A systematic review and meta-analysis. PLoS One 2016; 11: E0159827.
28. Herath SC, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2013; 11: CD009764.
29. Suzuki T, Yanai M, Yamaya M, et al. Erythromycin and common cold in COPD. Chest 2001; 120: 730-733.
30. Seemungal TAR, Wilkinson TMA, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Crit Care Med 2008; 178: 1139-1147.
31. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365: 689-698.
32. Uzun S, Djamin RS, Kluytmans JAJW, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): A randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2014; 2: 361-368.
33. Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med 2014; 189: 1503-1508.
34. Svanström H, Pasternak B, Hviid A. Cardiovascular risks with azithromycin. N Engl J Med 2013; 369: 580-581.
35. Ray WA, Murray KT, Meredith S, et al. Oral erythromycin use and the risk of sudden cardiac death. N Engl J Med 2004; 351: 1089-1096.
36. Mosholder AD, Mathew J, Alexander JJ, et al. Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med 2013; 368: 1665-1668.